We have also identified strong evidence for a harmful increase in cause-specific admissions due to heart failure from the use of COX2 inhibitors and pneumonia from the use of inhaled corticosteroids in COPD patients. Here, PTGS2 is linked to susceptibility to pneumonia measurement.